Reneo Pharmaceuticals, a pharmaceutical company, agreed to merge with OnKure, a privately-held, clinical-stage biopharmaceutical company. Financial terms were not disclosed. “Following a thorough evaluation of strategic alternatives, the Reneo board of directors and management team believe that this anticipated transaction represents a compelling opportunity to deliver shareholder value as the OnKure team advances their PI3Kα inhibitors,” Mike Grey, Reneo Pharmaceuticals Executive Chairman and Founder.